Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa therapy for Parkinson's disease. Taking advantage of a monkey brain bank constituted to study the pathophysiology of levodopa-induced dyskinesia, we here report the changes affecting D1, D2 and D3 dopamine receptors within the striatum of four experimental groups of non-human primates: normal, parkinsonian, parkinsonian treated with levodopa without or with dyskinesia. We also report the possible role of arrestin and G protein-coupled receptor kinases.
Guigoni
C
C
Basal Gang, Laboratoire de Physiologie et Physiopathologie de la Signalisation Cellulaire, CNRS UMR 5543, Université Victor Segalen-Bordeaux 2, France.
Aubert
I
I
Li
Q
Q
Gurevich
V V
VV
Benovic
J L
JL
Ferry
S
S
Mach
U
U
Stark
H
H
Leriche
L
L
Håkansson
K
K
Bioulac
Bernard H
BH
Gross
Christian E
CE
Sokoloff
Pierre
P
Fisone
Gilberto
G
Gurevich
E V
EV
Bloch
Bertrand
B
Bezard
Erwan
E
D000978:Antiparkinson Agents / Q000009:adverse effects*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D017447:Receptors, Dopamine D1 / Q000502:physiology*; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D050637:Receptors, Dopamine D3
D000978:Antiparkinson Agents; C493593:DRD3 protein, human; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D007980:Levodopa